2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 15

Abnormal ZAP-70 Expression in B Cells: New Potential Role in Tolerance Breakdown
Abstract Number: 925

Abortive Viral Infection Becomes Macrophage Activation Syndrome in Mice with Chronically Elevated Interleukin-18: Evidence for Synergy with Cytotoxic Impairment
Abstract Number: 1465

Absolute Number of Regulatory T Cells Decreased While Osteopontin Increased in Peripheral Blood of New Onset Patients with Rheumatoid Arthritis
Abstract Number: 797

Absolute Reduction of Peripheral CD4+ Regulatory T Cells in Patients with Systemic Sclerosis and Its Restoration By Short-Term and Low Dose IL-2 Treatment
Abstract Number: 1931

Abundance of Plasma Microbial Small RNAs Are Predictive of Improvement in Disease Activity after DMARD Initiation for Rheumatoid Arthritis
Abstract Number: 420

Accelerated Knee Osteoarthritis Is Characterized By Destabilizing Meniscal Tears and Pre-Radiographic Structural Disease Burden
Abstract Number: 423

Accelerated Knee Osteoarthritis Is Characterized By Pre-Radiographic Degeneration of the Extensor Mechanism and Cruciate Ligaments: Data from the Osteoarthritis Initiative
Abstract Number: 2367

Acceptance Rate and Sociological Factors Involved in the Switch from Originator to Biosimilar Etanercept (SB4)
Abstract Number: 2183

Access to Prescription Drugs in Canada: Results from an Online Survey
Abstract Number: 730

Accrual of Atherosclerotic Vascular Events over 10 Years in a Multicentre Inception SLE Cohort
Abstract Number: 1607

Achievement of Cdapsa Low Disease Activity or Remission Is Associated with Control of Articular and Extra-Articular Manifestations of Active Psa in Subjects Treated with Apremilast
Abstract Number: 2985

Achievement of Remission in Two Early Rheumatoid Arthritis Inception Cohorts Implementing Different Treat-to-Target Strategies
Abstract Number: 1179

Achieving Important Improvement in WOMAC Pain and Function By Three Months Post-Surgery Influences Satisfaction 1 Year Following Total Knee Replacement (TKR)
Abstract Number: 1655

Achieving Remission in Psoriatic Arthritis By Early Initiation of TNF Inhibition: A Double-Blind, Randomized, Placebo-Controlled Trial of Golimumab + Methotrexate Versus Placebo + Methotrexate
Abstract Number: 1157

Acknowledged Biostatistical Help and the Quality of Statistical Analyses in Randomized Controlled Trials in Rheumatology

« Previous Page
1
…
6
7
8
9
10
…
202
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].